Status:

RECRUITING

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Lead Sponsor:

Nationwide Children's Hospital

Collaborating Sponsors:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Conditions:

Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)

Eligibility:

All Genders

1-17 years

Phase:

PHASE2

PHASE3

Brief Summary

The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in chil...

Detailed Description

The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in chil...

Eligibility Criteria

Inclusion

  • ≥ 40 weeks corrected gestational age to \< 18 years; AND
  • Admission to the PICU or CICU; AND
  • Onset of ≥ 2 new organ dysfunctions within the last 3 calendar days (compared to pre-sepsis baseline) as measured by the modified Proulx criteria; AND
  • Documented or suspected infection as the MODS inciting event.

Exclusion

  • Weight \<3kg; OR
  • Limitation of care order at the time of screening; OR
  • Patients at high likelihood of progression to brain death in opinion of the clinical team; OR
  • Moribund condition in which the patient is unlikely to survive the next 48 hours in opinion of the clinical team; OR
  • Current or prior diagnosis of hemophagocytic lymphohistiocytosis or macrophage activation syndrome; OR
  • Peripheral white blood cell count \< 1,000 cells/mm3 as the result of myeloablative therapy OR receipt of myeloablative therapy within the previous 14 days; OR
  • Known allergy to anakinra, or E. coli-derived products; OR
  • Known pregnancy; OR
  • Lactating females; OR
  • Receipt of anakinra within the previous 28 days; OR
  • Resolution of MODS by MODS Day 2; OR
  • Previous enrollment in the TRIPS study.

Key Trial Info

Start Date :

June 14 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 31 2027

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT05267821

Start Date

June 14 2022

End Date

August 31 2027

Last Update

September 2 2025

Active Locations (32)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (32 locations)

1

Children's of Alabama

Birmingham, Alabama, United States, 35233

2

Arkansas Children's Hospital

Little Rock, Arkansas, United States, 72202

3

Children's Hospital of Los Angeles

Los Angeles, California, United States, 90027

4

Benioff Children's Hospital - Oakland

Oakland, California, United States, 64609

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS | DecenTrialz